Nemtabrutinib (MK-1026, formerly ARQ 531) is a small molecule drug that works as a reversible
Bruton's tyrosine kinase
Bruton's tyrosine kinase (abbreviated Btk or BTK), also known as tyrosine-protein kinase BTK, is a tyrosine kinase that is encoded by the ''BTK'' gene in humans. BTK plays a crucial role in B cell development.
Structure
BTK contains five di ...
(BTK) inhibitor; unlike other BTK inhibitors it also works against some mutated forms of BTK.
Merck paid $2.7 billion to acquire the company ArQule and the drug, which is being investigated as a cancer treatment.
References
Tyrosine kinase inhibitors
Small-molecule drugs
Phenol ethers
Chloroarenes
Benzaldehydes
Pyrrolopyridines
{{pharma-stub